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CHAPTER 1 INTRODUCTION 
Missing data threaten the validity of clinical trials, yet receive little attention in the 
literature (O’Neill & Temple, 2012; Wood, White, & Thompson, 2004). Poor approaches for 
treating missing values can produce biased estimates, distorted statistical power, and invalid 
conclusions (Acock, 2005; Enders, 2010; Fichman & Cummings, 2003; Graham, 2012). These 
consequences are especially serious for phase III trials, which are intended to provide evidence 
of the efficacy and safety of medical treatments. The use of inadequate missing data methods can 
also impede the construction of valid prognostic models (Burton & Altman, 2004), undermine 
random assignment in randomized controlled trials (RCTs), and violate the intention to treat 
(ITT) approach to the analysis of clinical trial data.   
Statistical power (rejecting a false null hypothesis) has also received less attention than it 
deserves (Cohen, 1962, 1988, 1990; Murphy, Myors, & Wolach, 2009). The literature is replete 
with meta-analyses demonstrating the shockingly low (e.g., .25) power of clinical trials (e.g., 
Button et al., 2013; Moher, Dulberg, & Wells, 1994; Tsang, Colley, & Lynd, 2009).  The almost 
total lack of attention to Type II error (failure to reject a false null hypothesis) and its 
consequences have “worrying implications” (Williams & Seed, 1992, p. 321). In clinical 
research, a high probability of Type II error can lead to the underreporting of serious adverse 
events (e.g., death, major bleeding, serious infections) and erroneous conclusions of equivalent 
toxicity (Tsang et al., 2009). The conclusions derived from underpowered studies are often 
contradictory (Howard, Maxwell, & Fleming, 2000; Maxwell, 2004; Rossi, 1990) and make it 
difficult to draw coherent clinical inferences from the literature (Maxwell, 2004). Failing to 
detect the effects of treatments or interventions may also contribute to the premature termination 
of potentially valuable research (Cohen, 1962; Williams & Seed, 1993; Yuen & Pope, 2008) and 
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this is especially true when Type II errors are committed in exploratory studies involving 
innovative designs or small treatment effects (Chase & Chase, 1976; Freiman, Thomas, 
Chalmers, Smith, & Kuebler, 1978; Woods, Rippeth, Conover, Carey, Parsons, & Tröster, 2006).  
 Unfortunately, the consequences of underpowered studies are often exacerbated by the 
use of outdated missing data techniques. Listwise deletion (the practice of discarding cases with 
one or more missing values) has been shown to drastically increase the probability of a Type II 
error, yet still continues to dominate the RCT literature (Mackinnon, 2010; Wood et al., 2004), 
even in areas such as cancer research (Burton & Altman, 2004). Multiple appeals have called for 
the abandonment of traditional approaches (including listwise deletion) in favor of more 
principled methods (see Chapter 2).  
 Multiple imputation (MI) is a promising approach to treating missing data. First proposed 
by Rubin (1976) and elaborated in 1987, MI replaces missing values with m > 1 sets of imputed 
values, resulting in m complete datasets. Each of the datasets is analyzed and the results are 
combined to yield one set that reflects both within- and between-imputation uncertainty.  
Initial MI procedures assumed a large joint model for variables (e.g., a joint normal 
distribution). As almost all datasets have mixtures of incomplete categorical and continuous 
variables, this assumption rarely holds in practice. Fully conditional specification (FCS) or 
multiple imputation using chained equations (MICE) is a flexible alternative to joint models. The 
procedure specifies an individual regression model for each variable using the other variables in 
the model as predictors. 
 Empirical evidence has suggested that MI is unbiased when the data are normally 
distributed (e.g., Choi, Golder, Gillmore, & Morrison, 2005; Collins, Schafer & Kam, 2001; 
Graham & Schafer, 1999; Raghunathan, Lepkowski, Van Hoewyk, & Solenberger, 2001; Van 
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Buuren, Brand, Groothuis-Oudshoorn, & Rubin, 2006), but its performance under nonnormality 
is unclear. A simulation by Demirtas, Freels and Yucel (2008) showed that MI performed 
reasonably well when the normality assumption was clearly violated and the sample was 
relatively large (n > 400). According to Van Buuren (2012), the effect of nonnormality is 
generally small for measures that rely on the center of the distribution but could be substantial 
for other types of estimates. A simulation involving several sequential regression MI methods 
(and extensions which adjust for nonnormal error terms) found that MI performed well for 
estimating marginal means and regression coefficients when the error distribution was flat or 
moderately heavy tailed but had poor performance when the distribution was strongly heavy 
tailed (He and Raghunathan, 2009).  
 Although MI has been successfully used in large epidemiologic and biomedical datasets 
(e.g., Centers for Disease Control and Prevention AIDS surveillance system, National Health and 
Nutrition Examination Survey, National Medical Expenditure Survey), its small sample 
properties are unclear. Early research by Graham & Schafer (1999) showed that MI performed 
well when samples were small (n = 50), but recent simulations suggest that MI may have biases 
in small samples, even when the data are normally distributed (Demirtas et al., 2008; Von 
Hippel, 2013b). 
 Given its potential for improving the validity of RCT results (Sterne et al., 2009), there 
has been a call for investigations into MI’s properties and limitations (Enders, 2010; Graham, 
2012; Lee & Carlin, 2012; Rässler, Rubin & Zell, 2013; Stuart, Azur, Frangakis, & Leaf, 2009). 
In addition to an appeal for more systematic research, there have been specific requests for 
investigations into MI’s effect on small samples (Von Hippel, 2004) and power (Davey & Savla, 
2010; Young, Weckman & Holland, 2011). In a call to action, the National Academy of Science, 
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in a special report to the Food and Drug Administration (2010), urged sponsors of clinical trials 
to make the treatment of missing data a priority, proposed that approved missing data techniques 
be limited to those that account for the uncertainty attributable to missing data (e.g., MI), and 
identified several high priority areas for missing data research (e.g., the effect of missing data on 
power, the robustness of missing data methods, and the development of software that supports 
coherent missing data analysis).  
 In response to demands for more principled methods of handling missing data, IBM 
SPSS Statistics (hereafter referred to as SPSS) added easy to implement MI routines based on the 
chained equation approach (see Grace & Sawilowsky, 2009, for a comparison of missing data 
software). By eliminating the need for specialized software and advanced analytical training, the 
program allows clinicians, unfamiliar with MI, to utilize the technique when analyzing 
incomplete data. 
Statement of the Problem 
 Methodologists have described missing data as “one of the most important statistical and 
design problems in research” (methodologist William Shadish, cited in Azar, 2002, p. 70). The 
National Academy of Science (2010) identified numerous high priority areas for missing data 
research that are echoed in the literature. This study will address several of those areas by 
systematically investigating the impact of MI on the rejection rate of the independent samples t 
test (also referred to as the t test) under a range of conditions that reflect the interplay of 
complexities that arise when analyzing differences between treatment arms in RCTs. More 
specifically, this investigation will utilize a factorial design that will examine eight sample sizes, 
five treatment effect sizes, three fractions of missing data, three distributions, and two alpha 
levels to determine if MI impacts Type II error in RCTs. 
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In addition to identifying areas for missing data research, the National Academy of 
Science (2010) urged analysts and clinical reviewers to become familiar with current missing 
data terminology and techniques. To help clinicians meet this objective, this study also seeks to 
provide an overview of the MI procedure, as implemented in SPSS, with a focus on the practical 
aspects and challenges of using this method.  
Human Participants 
 This research will utilize a Monte Carlo simulation approach that does not involve human 
subjects. 
Declaration of Interest 
 The author has no competing interests. 
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Table 1 
Abbreviations & Symbols 
 
Abbreviation  
or Symbol 
 
Definition 
 The probability of making a Type I error 
 The probability of making a Type II error (1-  denotes statistical power) 
CI Confidence interval 
d Effect size (Cohen’s d) 
df Degrees of freedom 
ES Effect size 
FCS  Fully conditional specification  
FMI (γ) 
HRR 
Fraction of missing information 
Highest rejection rate 
ITT Intention to treat 
λ Proportion of variance attributable to missing data 
LD 
LRR 
Listwise deletion (also referred to as complete case analysis) 
Lowest rejection rate 
MAR Missing at random 
MCAR Missing completely at random 
MICE Multiple imputation by chained equations 
MIS Missing 
MS Mean substitution 
MNAR Missing not at random 
MI Multiple imputation 
μ Population mean 
n Number of cases (generally in a subsample) 
OBS Observed 
PD 
PDI 
Pairwise deletion 
Percentage of data imputed 
θ Parameter of interest 
RCT Randomized controlled trial 
RE Relative efficiency 
RI Regression imputation 
σ Population standard deviation 
SPSS IBM SPSS Statistics 
t test Independent samples t test 
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CHAPTER 2 LITERATURE REVIEW 
 Because RCTs create equivalent groups (i.e., balance prognostic factors) by randomly 
assigning participants to different treatment arms, they allow researchers to draw causal 
conclusions about the efficacy and adverse effects of treatments or interventions. Less than 
optimum strategies for treating missing values can undermine random assignment and seriously 
compromise the validity of clinical trials. MI is a promising alternative to traditional methods 
that has been shown to be unbiased when the data are normally distributed (e.g., Choi, et al., 
2005; Collins, et al., 2001; Graham & Schafer, 1999; Raghunathan, et al., 2001; Van Buuren et 
al., 2006), but its small sample properties and performance under nonnormality are unclear. The 
purpose of this study is to investigate the impact of MI on the rejection rate of the independent 
samples t test under varying conditions of sample size, effect size, fraction of missing data, 
distribution shape, and alpha. To provide readers with a solid understanding of the different 
facets of this research, this chapter is divided into three sections. The first section provides an 
overview of missing data, including its theoretical underpinnings. More specifically, it examines 
missing data mechanisms, patterns of missing data, traditional approaches to the handling of 
missing data, and the pervasiveness of traditional approaches. The second section provides a 
foundation for understanding the outcome of this study. It explains statistical power, the almost 
total lack of attention to Type II error in the literature, and the impact of Type II error on the 
validity of RCTs. The final section reviews the results of previous investigations into the 
performance of MI; describes the MI procedure, as implemented in SPSS, with a focus on the 
practical aspects and challenges of using this method; and examines the robustness of the 
statistical test that will be used in the analysis phase of the MI procedure. 
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Overview of Missing Data 
Missing data can seriously affect the validity of clinical research (McKnight, McKnight, 
Sidani, & Figueredo, 2007). The magnitude of the impact depends on the mechanisms that led to 
the missing data, the amount of missing data, and the pattern of missing data (McKnight, et. al, 
2007; Tabachnick & Fidell, 2007). 
Mechanisms. Rubin (1976) identified three missing data mechanisms that serve as 
probabilistic explanations for how missing values are related to variables in a dataset. The 
mechanisms are not characteristics of the dataset but rather assumptions that apply to specific 
analyses. Although it is often difficult to discern the form of mechanisms (Collins et al., 2001), a 
sensitivity analysis conducted by Graham, Hofer, Donaldson, Mackinnon, and Schafer (1997) 
showed that the effects of inaccessible mechanisms are minimal in the implementation of MI. 
The mechanisms can be classified as missing completely at random (MCAR), missing at random 
(MAR), and missing not at random (MNAR). 
 Although MCAR is a strict assumption that is rarely satisfied in practical applications 
(Acock, 2005; Enders, 2001; Raghunathan, 2004), it is the principal assumption underlying the 
traditional approaches to missing data. Under the MCAR condition, missing values are not 
related to either observed or missing values in a dataset. Because the distribution of missing 
values cannot be predicted, the observed data can be treated as a simple random sample and the 
mechanism capturing the reason for the missing values can be ignored for sampling-based and 
likelihood-based inferences (Little & Rubin, 2002). Using Rubin’s (1976) notation, the MCAR 
mechanism can be represented by 
p (R|θ) 
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where p is the probability distribution, R is the response indicator (observed or missing), and θ is 
a parameter that describes the relationship between R and the data.  
 MCAR is the only missing data mechanism that is testable. Although it does not provide 
definitive evidence, Little’s (1988) multivariate test can assess whether the MCAR condition is 
tenable (Littell, Roderick, & Schenker, 1995). The test produces a chi-square value that 
compares the observed variable means for each pattern of missing data with the expected 
population means. If the test is significant, the data are not MCAR. Although MCAR is not an 
assumption of MI, the test is still useful for identifying correlates of missingness that should be 
included in the imputation model. MI has been shown to be unbiased and efficient under the 
MCAR condition (Enders, 2006). 
 The MAR mechanism is less restrictive and more tenable than MCAR and is the principal 
assumption required for most forms of imputation. Under this condition, missing values are 
related to observed values, but not to missing values. The MAR mechanism can be represented 
by  
p (R|Yobs, θ) 
where p is the probability distribution, R is the response indicator (observed or missing), Yobs is 
the observed data, and θ is a parameter that describes the relationship between R and the data. 
MAR is the most common mechanism in epidemiologic research (Moons, Donders, Stijnen, & 
Harrell, 2006) and MI has been shown to be unbiased and efficient under this condition (Buhi, 
Goodson, & Neilands, 2008; Little & Rubin, 2002). Because MI does not require information 
about θ, the mechanism capturing the reason for missing data can be ignored.  
 The MNAR condition is present when missing values are related to the values that are 
missing and cannot be ignored. The mechanism can be represented by  
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p (R|Yobs, Ymis, θ) 
where p is the probability distribution, R is the response indicator (observed or missing), Yobs is 
the observed data, Ymis is the missing data, and θ is a parameter that describes the relationship 
between R and the data. MI has been shown to perform reasonably well under the MNAR 
condition (Collins et. al, 2001; Sinharay, Stern, & Russell, 2001), even with 25% of the data 
missing (Buhi et al., 2008). Using a nonignorable imputation model (Van Buuren, 2012) or 
including variables that account for missingness in the imputation model (Moons et al., 2006; 
Van Buuren, 2012) can reduce the impact of MNAR. Readers who are interested in MNAR 
analysis methods are referred to Enders, 2010. 
 Amount of missing data. There is not a consensus regarding the percentage of missing 
data that can be tolerated by RCTs. Even a few MNAR values can seriously affect the 
generalizability of results (Tabachnick & Fidell, 2007). Evidence suggests that the bias 
introduced by the fraction of missing data may depend on the method used to address the 
problem. A simulation by Berlin (2009) demonstrated that listwise deletion could incorrectly 
yield a nonsignificant treatment effect (i.e., a Type II error) with only 5% of the data missing. In 
contrast, Choi et al. (2005) showed that MI (as employed in the statistical programs EMCOV, 
NORM, Amos, and Mplus) could provide parameter estimates that come close to those of the 
population with 50% of the data missing.  
 Missing data patterns. The MI procedure recognizes two patterns of missing data: 
monotone and arbitrary. Readers who are interested in other missing data patterns (e.g., latent 
variable, missing by design) are directed to Enders, 2010; and Little & Rubin, 2002. A monotone 
pattern (Figure 1) is typically associated with attrition (Enders, 2010; Rässler et al., 2013) and is 
present when data on an individual measurement are missing on all subsequent measurements. 
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Let Yj be the jth variable,  j = 1, 2, … , p in a dataset. Having a missing value on variable Yj also 
means having missing values on all of the following variables Yj + 1,   , Yp. The univariate 
pattern (Figure 2) is a special type of monotone pattern that occurs when missing values are 
confined to a single variable. This pattern frequently occurs in experimental studies (Enders, 
2010). If the data follow a monotone pattern, SPSS imputes the missing values using a 
noniterative estimation algorithm (see Schafer, 1997, p. 218 – 238 for discussion). The arbitrary 
pattern (Figure 3) is present when missing values are randomly dispersed throughout the data 
matrix. If the data follow this pattern, SPSS uses an iterative Markov chain Monte Carlo method 
to impute the missing values. 
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35         35 
5        X 40 
5       X X 45 
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5     X X X X 55 
5    X X X X X 60 
a. Variables are sorted on missing patterns.  
b. Number of complete cases if variables missing in that pattern (marked with X) are not used. 
 
Figure 1. Monotone pattern of missing data. Simulated SPSS output. 
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a. Variables are sorted on missing patterns.  
b. Number of complete cases if variables missing in that pattern (marked with X) are not used. 
 
Figure 2. Univariate pattern of missing data. Simulated SPSS output 
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1   X    X  49 
1   X      45 
a. Variables are sorted on missing patterns. 
b. Number of complete cases if variables missing in that pattern (marked with X) are not used 
 
Figure 3. Arbitrary pattern of missing data. Simulated SPSS output. 
 
Traditional Approaches to Missing Data 
Missing data threaten the validity of clinical trials, yet receive little attention in the 
literature (O’Neill & Temple, 2012; Wood et al., 2004). Poor approaches for treating missing 
values can produce biased estimates, distorted statistical power, and invalid conclusions (Acock, 
2005; Enders, 2010; Fichman & Cummings, 2003; Graham, 2012). These consequences are 
especially serious for phase III trials, which are intended to provide evidence of the efficacy and 
safety of medical treatments. The use of inadequate missing data methods can also impede the 
construction of valid prognostic models (Burton & Altman, 2004), undermine random 
assignment in RCTs, and violate the ITT approach to the analysis of clinical trial data.  
 Given their potential to compromise inferences from RCTs, a brief overview of 
traditional techniques is warranted. Although a multitude of approaches have been proposed in 
the literature, the focus on cross-sectional designs precludes an exhaustive review of these 
methods. Readers who are interested in procedures that are utilized in repeated measures designs 
(e.g., last observation carried forward) are directed to Allison, 2001; Little and Rubin, 2002; and 
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Schafer and Graham, 2002. Although the following techniques are supported in SPSS, the 
literature is replete with illustrations that show the detrimental effects these approaches have on 
results (e.g., Acock, 2005; Allison, 2001; Baraldi & Enders, 2010; Enders, 2010; Enders & 
Bandalos, 2001; Graham & Schafer, 2002; Olinsky, Chen, & Harlow, 2003; Raghunathan, 2004; 
Schafer & Graham, 2002). 
 Listwise deletion (LD) is also known as complete case analysis and is the default in SPSS 
(and most other standard statistical packages). Although Graham and Donaldson (1993) describe 
special cases where LD did not bias estimates under MAR, most of the literature confirms that 
LD biases estimates while underestimating variances, covariances, and correlations when the 
data do not meet the MCAR assumption (e.g., Enders & Bandalos, 2001; Graham & Schafer, 
2002; Von Hippel, 2004).  Because LD discards every case that has one or more missing values, 
it can drastically reduce sample size. According to Acock (2005), LD typically results in 
discarding 20% to 50% of the data (p. 1015). This loss substantially increases the risk of a Type 
II error and the reduction in power can be devastating, even for large samples with relatively 
small amounts of missing data. Choi et al. (2005) illustrated how the use of LD completely 
obliterates power. In their demonstration, the authors showed how removing 20% of the data 
reduced their sample from 463 to 32 and how removing 50% of the data reduced their sample 
from 463 to 1. As the nondiscarded cases may not be representative of the population, LD 
undermines external validity (Allison, 2001; Enders, 2010; Schafer & Graham, 2002) and 
violates the ITT approach to the analysis of clinical trial data. 
 Pairwise deletion (PD) is also known as available case analysis and uses the observed 
data for each analysis without attempting to restore the rectangular form of the data matrix 
(which in some procedures, like structural equation modeling, may prevent a solution). 
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According to McKnight et al. (2007), “large discrepancies between the number of available cases 
for each of the variables in the analysis often produce interpretation problems that are 
insurmountable” (p. 99). Because the appropriate degrees of freedom for tests of significance are 
ambiguous, the estimated standard errors and test statistics produced by conventional software 
are biased and tend to increase Type II errors (Allison, 2001). In models involving only one or 
two variables (e.g., t test, one way ANOVA), LD and PD are identical methods. 
 Mean substitution (MS) replaces missing values with the mean of observed values. 
According to Acock (2005), “the mean substitution approach is probably the worst solution to 
missing values because it attenuates variance and often provides poor imputed values” (p. 1025). 
Because each imputed value falls directly on a straight line with a slope of zero, MS can 
dramatically attenuate correlations between variables (Baraldi & Enders, 2010). The appreciable 
bias observed when MS is used should cause concern because it can lead to a substantial 
reduction in power (Schlomer, Bauman, & Card, 2010). Schlomer et al. (2010) illustrated how 
the use of MS would have led to the incorrect conclusion that there was no difference between 
two treatments when there was actually a large difference between the arms. 
 Regression imputation (RI) replaces missing values with predicted values obtained from 
a linear regression equation without incorporating a stochastic component to account for 
uncertainty. Consequently, RI underestimates variance and lacks the variability that would be 
present in the hypothetically complete dataset. Because imputed values fall directly on a straight 
line with a nonzero slope, RI overestimates correlations (Baraldi & Enders, 2010), even when the 
data are MCAR (Enders, 2010).  
Despite the fact that Wilkinson and the Task Force on Statistical Inference (1999) 
declared LD and PD “among the worst methods available for practical applications” (p. 598), 
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these techniques continue to dominate the literature – even in high-impact medical journals with 
stringent statistical review policies. Wood et al. (2004), for example, reviewed 71 RCTs 
published between July 2001 and December 2001 in four prestigious medical journals (i.e., 
Journal of the American Medical Association, British Medical Journal, The Lancet and New 
England Journal of Medicine). The authors found that LD was used in 92% of the cross-sectional 
and 46% of the repeated measures designs, and noted that the use of this technique has the 
potential to cause substantial bias in treatment effect estimates. The findings of Peugh & Enders 
(2004) also corroborate the popularity of LD. In their review of 23 applied research journals 
published in 1999 and 2003, they found that 96% of the studies used LD or PD.  
 The use of LD also extends to medical research conducted with strict oversight. Harel, 
Pellowski, and Kalichman (2012) reviewed 57 RCTs maintained by the HIV/AIDS Prevention 
Research Synthesis Project at the Centers for Disease Control in June 2010 and found that LD 
was used in 74% of the studies. Under relaxed assumptions, the authors “expect only 12% of the 
studies to report unbiased results” (p. 1382). 
Klebanoff and Cole (2008) attempted to document the use of MI procedures appearing in 
the epidemiologic literature (i.e., American Journal of Epidemiology, Annals of Epidemiology, 
Epidemiology, and International Journal of Epidemiology) from January 2005 to December 
2006, but the rarity of MI use precluded analysis. In a similar attempt to document the transition 
from traditional methods to more principled methods, Mackinnon (2010) recorded the number of 
MI studies appearing in four medical journals (i.e., Journal of the American Medical 
Association, New England Journal of Medicine, British Medical Journal, and The Lancet) at two 
time points (before 2005 and from 2005 to 2008). Although Mackinnon reported that the use of 
MI in clinical trials has “risen substantially” (2010, p. 586), the increase was based on an 
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extremely small number of publications (e.g., an increase from 1 RCT appearing in the New 
England Journal of Medicine before 2005 to 4 appearing from 2005 to 2008). 
The Lack of Attention to Power in the Literature 
 Statistical power (rejecting a false null hypothesis) has received less attention than it 
deserves (Cohen, 1962, 1988, 1990; Murphy et al., 2009). The almost total lack of attention to 
Type II error (failure to reject a false null hypothesis) and its consequences have “worrying 
implications” (Williams & Seed, 1992, p. 321). In clinical research, a high probability of Type II 
error can lead to the underreporting of serious adverse events (e.g., death, major bleeding, 
serious infections) and erroneous conclusions of equivalent toxicity (Tsang et al., 2009). The 
conclusions derived from underpowered studies are often contradictory (Howard, et al., 2000; 
Maxwell, 2004; Rossi, 1990) and make it difficult to draw coherent clinical inferences from the 
literature (Button et al., 2013; Maxwell, 2004). Not only do underpowered studies lead to a 
confusing literature, they also adversely affect future research by creating a reference literature 
that contains biased effect size estimates (Maxwell, 2004). Failing to detect the effects of 
treatments or interventions may also contribute to the premature termination of potentially 
valuable research (Cohen, 1962; Williams & Seed, 1993; Yuen & Pope, 2008) and this is 
especially true when Type II errors are committed in exploratory studies involving innovative 
designs or small treatment effects (Chase & Chase, 1976; Freiman et al., 1978; Woods et al., 
2006). Rosenthal (1990) provided an example that demonstrates how aspirin would have been 
deemed ineffective in preventing heart attacks (with an r2 = .001) if the trial had not been 
sufficiently powered. 
Although the literature is replete with warnings about the potentially disastrous impact of 
underpowered studies, recommendations by Wilkinson and the Task Force on Statistical 
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Inference (1999) to improve statistical practice have gone unheeded. A review of the literature 
showed that RCTs are often inadequately powered to detect iatrogenic effects.  
In a trial comparing fixed-dose, weight adjusted unfractionated heparin with low 
molecular weight heparin for the treatment of venous thromboembolism, Kearon et al. (2006) 
failed to find a significant difference in the frequency of major bleeding events despite observing 
twice as many events in the low molecular weight group (12 out of 352) than in the 
unfractionated group (6 out of 345). A subsequent evaluation of the trial revealed that the power 
to detect the difference in the proportions was .30 (Tsang et al., 2009). 
The failure of Kearon et al. (2006) to detect adverse effects is not uncommon. In an 
investigation into the cognitive effects of subthalamic nucleus deep brain stimulation in 
Parkinson’s disease, Woods et al. (2006) reviewed 30 studies published between 1997 and 2004 
and found that only 7% of the studies demonstrated adequate power (≥ .80) to detect the 
cognitive decline associated with large (f = .40) effects.  
In a similar meta-analysis, Tsang et al. (2009) reviewed six RCTs published between 
January 2006 and March 2007 to determine if RCTs were sufficiently powered to detect serious 
adverse events. Their results revealed statistical power levels that ranged from .07 to .37. The 
authors noted that erroneous conclusions of equivalent efficacy and toxicity were being drawn 
(p. 610). 
A review of the literature has also shown that RCTs are often inadequately powered to 
detect treatment effects. Yuen & Pope (2008) investigated the power of RCTs in the treatment of 
non-renal SLE. Their review of 30 negative trials published between 1975 and 2007 revealed a 
mean statistical power of .25. The authors found that only one of the RCTs demonstrated 
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adequate power ( .80). They concluded that useful therapies could be discarded (p. 1369) and 
that “the generalizability of SLE trials was modest at best” (p. 1370). 
Pike & Leith (2009) also found that RCTs are underpowered. They examined 29 
superiority trials appearing in the orthopedic literature from 1994 to 2007. Their results revealed 
a mean statistical power of .41.  The authors concluded that none of the trials were sufficiently 
powered to detect a small treatment effect, two (6.9%) were sufficiently powered to detect a 
medium treatment effect, and 13 (44.8%) were sufficiently powered to detect a large treatment 
effect.  
In a comprehensive examination of power in the neuroscience field, Button et al. (2013) 
reviewed 49 meta-analyses (comprised of 730 primary studies) published in 2011 and found that 
the median statistical power was .21. The authors concluded that “there is now substantial 
evidence that a large proportion of the evidence reported in the scientific literature may be 
unreliable” (p. 374). 
In an older investigation of Type II error, Brown, Kelon, Ashton, and Werman (1987) 
examined 13 negative RCTs appearing in the emergency medicine literature from 1972 to 1984 
and found that the statistical power ranged from .03 to .40. They noted that for the endpoints 
examined, a sample size of up to 450 times larger than that used would have been required to 
detect a clinically important difference. According to the authors, “this raises serious ethical 
issues because study subjects were enrolled in a trial that at the outset was doomed to be 
negative” (p. 187).  
To assess changes in statistical practice, Moher et al. (1994) compared 102 negative 
RCTs published over a 20-year period (1975, 1980, 1985, and 1990) and concluded that the 
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statistical power of RCTs has not improved over time. Current meta-analyses (e.g., Button et. al., 
2013; Yuen & Pope, 2008) collaborate Moher et al.’s (1994) findings. 
The prevalence of underpowered RCTs in the literature may result from a 
misunderstanding of alpha, beta, and power by the clinical community (Cohen, 1992). To clarify, 
a Type I error (α) is the probability of finding a statistical difference between treatment arms 
when the treatments are equivalent (rejecting a true null hypothesis). A Type II error (β) is the 
probability of not finding a statistical difference between treatment arms when the treatments are 
not equivalent (failure to reject a false null hypothesis). Power is the probability of detecting a 
difference between treatment arms when the treatments are not equivalent (rejecting a false null 
hypothesis) and can be defined as 1 – β.  
Power is a function of alpha (α), sample size (n), and effect size (ES). Increasing any of 
these parameters will increase the power of a statistical test. Cohen (1965) recommended that 
power = .80 (β = .20) when α = .05. This proposes a 4:1 : ratio. According to Cohen (1992), 
“a materially smaller value than .80 would incur too great a risk of a Type II error. A materially 
larger value would result in a demand for n that is likely to exceed the investigator’s resources” 
(p. 156). The following illustrations, created with G*Power 3 (Faul, Erdfelder, Lang and 
Buchner, 2007), show how reducing n1, n2 from 60, 60 (Figure 4) to 10, 10 (Figure 5), at alpha 
.01, increases the probability of committing a Type II error (β) from 4% to 83% when a large 
(0.80) treatment effect is present. 
Cohen (1988) suggested a number of conventions for describing treatment effects as 
small, medium or large. The recommended effect sizes (d) for the independent samples t test are 
0.2σ for a small effect, 0.5σ for a medium effect, and 0.8σ for a large effect. Sawilowsky (2009) 
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extended Cohen’s work to include very small (0.01σ), very large (1.2σ), and huge (2.0σ) effect 
sizes.  
 
Figure 4. Two-tailed t test, n1, n2 = 60, 60; d = 0.80; α = .01, power = .959 
 
 
 
Figure 5. Two-tailed t test, n1, n2 = 10, 10; d = 0.80; α = .01, power = .172 
  
Multiple Imputation 
Multiple imputation (MI) is a promising approach to treating missing data. First proposed 
by Rubin (1976) and elaborated in 1987, MI replaces missing values with m > 1 sets of imputed 
values, resulting in m complete datasets. Each of the datasets is analyzed and the results are 
combined to yield one set that reflects both within- and between-imputation uncertainty. By 
accounting for the variability between imputations, MI allows the uncertainty in the imputation 
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process to be quantified and integrated into the analysis, which allows it to provide accurate 
inferential conclusions (Schlomer et al., 2010). 
A plethora of simulation studies show MI estimates to be unbiased (e.g., Choi et al., 
2005; Collins, et al., 2001; Graham & Schafer, 1999; Raghunathan et al., 2001; Van Buuren et 
al., 2006). A simulation by Choi et al. (2005) showed that MI provided parameter estimates that 
came close to those of the population with 50% of the data missing. These results were 
corroborated by Marshall, Altman, Royston, and Holder (2010) who also reported MI to be 
useful when up to 50% of the values were missing. Although these results are encouraging, there 
may be an upper limit to the amount of missing data that can be tolerated by MI. Barzi and 
Woodward (2004) revealed inflated variability and convergence problems with some MI 
techniques when more than 60% of the observations had missing data (with varying results 
depending upon the imputation technique).  
Nonnormality. MI procedures are somewhat robust against violations of normality (as 
far as bias is concerned). According to Van Buuren (2012), the effect of nonnormality is 
generally small for measures that rely on the center of the distribution but could be substantial 
for other types of estimates. Demirtas et al. (2008) found that with a fairly large sample (n > 
400), MI performed reasonably well when the normality assumption was clearly violated (i.e., 
flatness of the density, heavy tails, non-zero peakedness, skewness, and multimodality), even 
when there was a high percentage (75%) of missing data. Graham and Schafer (1999) conducted 
a simulation in which highly nonnormal variables were imputed under normality assumptions 
with no transformations or rounding and reported excellent performance for linear regression. 
Von Hippel (2013a) imputed skewed variables from a normal model and found that they 
produced acceptable estimates for means, variances, and regressions. A simulation of several 
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sequential regression MI methods (and extensions which adjust for nonnormal error terms) found 
that when the error distribution was flat or moderately heavy tailed, MI was able to estimate 
marginal means and regression coefficients, but when the distribution was strongly heavy tailed, 
the regression coefficients were biased (He & Raghunathan, 2009).  
Despite MI’s potential for poor performance under conditions of extreme skew, strong 
concerns over the use of transformations (in the context of MI) have been raised (e.g., Demirtas 
et al., 2008, p. 82 – 83). After testing several methods for adapting a normal imputation model to 
accommodate skew (e.g., transform, truncate or round), Von Hippel (2013a) found that none of 
the modifications reliably reduced bias (and some modifications made the bias much worse). 
Enders (2010) pointed out that because MICE relies on the associations among variables and 
transformations can alter the covariate structure of the data, transforming (then back 
transforming) the data could affect the accuracy of the imputations and resulting estimates. 
MNAR. MI has been shown to perform reasonably well under the MNAR condition 
(Collins et al., 2001; Sinharay et al., 2001; Carpenter, Kenward, & White, 2007) with a moderate 
amount (25%) of missing data (Buhi et al., 2008; Collins, et al., 2001). Under more extreme 
conditions (i.e., the missing data rate exceeds 25% or in the case of a linear regression r > .40), 
the form of the mechanism (whether the probability to be missing was linear or was more likely 
to occur in the extremes) determined which parameters were affected (Collins et al., 2001). The 
impact of MNAR can be reduced by including auxiliary variables that account for missingness in 
the imputation model (Moons et al, 2006; Van Buuren, 2012) or by using a nonignorable 
imputation model (Van Buuren, 2012). 
Small Samples. Although MI has been successfully used in large epidemiologic and 
biomedical datasets (e.g., Centers for Disease Control and Prevention AIDS surveillance system, 
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National Health and Nutrition Examination Survey, National Medical Expenditure Survey), its 
small sample properties are unclear. Graham and Schafer (1999) showed that MI performed well 
when samples were small (n = 50) and a large proportion (50%) of the data were missing. In fact, 
some of the analyses based on MI data were as good as the same analyses performed on 
complete data (Graham & Schafer, 1999). Barnes, Lindborg and Seaman (2006) showed that 
common regression based MI methods provided close to ideal CI coverage for 20% dropout in 
small (n = 20, 30, 50) clinical trials, but some methods fell short when the percentage of missing 
data increased to 30 or 40%. Von Hippel (2013b) demonstrated that bias occurred when the 
samples were small (n = 25), there was a large amount of missing data (50%), and the missing 
values followed an exceptionally challenging pattern. Demirtas et al. (2008) also showed that MI 
produced biased estimates when samples were small (n = 40) and a large amount (75%) of data 
were missing. Simulations by Kim (2004) showed that decreasing the sample size from 200 to 
20, increased the variance of point estimators by a factor of 10 or more depending upon the 
proportion of missing data.  
Multiple Imputation in Practice 
 Initial multiple imputation procedures assumed a large joint model (e.g., a joint normal 
distribution). As almost all datasets have mixtures of incomplete categorical and continuous 
variables, this assumption rarely holds in practice. MICE is a flexible alternative to joint models 
that does not assume that the data have an underlying normal distribution (Johnson & Young, 
2011; Schafer, 1999; Van Buuren, 2012). It also does not assume that nonresponse is ignorable 
(Schafer, 1999). In principal, imputations can be created under any missing data mechanism and 
the inferences will be valid under that mechanism (Schafer, 1999). The MI procedure has three 
phases: imputation, analysis, and pooling. 
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 The imputation phase. During this phase, the MI procedure creates several complete 
versions of the dataset by iteratively replacing missing values with imputed values. The MICE 
approach accomplishes this by specifying an individual regression model for each variable using 
the other variables in the model as predictors p (Yjmis | Yjobs ,Y-j, R). In contrast to joint modeling, 
MICE specifies the multivariate distribution p (Y, X, R | θ) through a set of conditional densities   
p (Yj | X,Y-j, Rϕj). The conditional density is used to impute Yj given X, Y-j and R which allows 
each variable to be modeled according to its distribution. SPSS uses logistic regression to impute 
incomplete binary and categorical variables, and linear regression or predictive mean matching 
(a variant of linear regression that matches imputed values computed by the regression model to 
the closest observed value) to impute continuous variables.  
 There are several ways to implement imputation under conditionally specified models. 
The MICE algorithm starts with simple random draws from the marginal distribution and 
sequentially imputes each variable in the order specified in the variable list (e.g., by missing 
value rates) until the iteration is complete and all of the variables have been imputed. The 
process repeats using the Gibbs sampling procedure (a Bayesian simulation technique that 
samples from the conditional distributions in order to obtain samples from the joint distribution) 
for a specified number of iterations (in SPSS, the default is 10). A number of simulations have 
shown that unbiased estimates and appropriate coverage is obtained after 5 – 10 iterations 
(Raghunathan et al., 2001; Van Buuren, 2012; Van Buuren & Groothuis-Oudshoorn, 1999; 
White, Royston, & Wood, 2011). When the specified number of iterations has been reached, the 
distribution of parameters governing the imputations should have converged. At convergence, 
the complete dataset is retained and the entire process is repeated m times resulting in m 
complete datasets being stacked with the original incomplete dataset in the SPSS data file.  
  
25 
When choosing variables to include in the imputation model, a simulation by Collins et 
al. (2001) showed that an inclusive strategy is superior to a restrictive strategy “because there 
appear to be few risks associated with it and potentially substantial gains” (p. 350). Although 
there has been some disagreement on the subject (see Hardt, Herke & Leonhart, 2012), the 
prevailing view is that the imputation model should include: (a) target variables (variables that 
will be used in the analysis phase); (b) auxiliary variables (variables intended to predict 
missingness or improve the model, including variables that preserve correlations and 
interactions; Collins et al., 2001; Piggot, 2001; Rubin, 1996; Schafer & Olsen, 1998; Sinharay et 
al., 2001); (c) sample variables (variables that describe aspects of clustered, stratified or 
longitudinal data); and (d) outcome variables (Collins et al., 2001; Enders, 2010; Little, 1992; 
Moons et al., 2006). 
Although it seems counterintuitive, including outcome variables in the imputation model 
is necessary to reduce bias when imputing predictor variables and does not overestimate the 
regression coefficients between outcomes and predictors (Moons et al., 2006). Failing to include 
variables that mediate between outcomes and predictors can also result in bias and loss of power 
(Collins et al., 2001; Enders, 2010). When interactions are not modeled, the effects of the 
correlations (and interactions) between the variables will be biased towards zero (Graham, 2009; 
Sterne et al., 2009). Variables with missing information should also be included in the 
imputation model. Although this also seems counterintuitive, simulations have shown that 
auxiliary variables with missing values are nearly as effective in reducing bias as those with no 
missing values (Enders, 2010). It should be noted, however, that including variables with large 
fractions of missing information can slow or prevent convergence (Van Buuren & Groothuis-
Oudshoorn, 1999).  
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Although including a diverse set of variables in the imputation model may reduce bias, 
there seems to be an upper limit to the number of variables that can be modeled. Chained 
equations break down at a 1:1 ratio of variables to cases, even with small fractions of missing 
data (Hardt et al., 2012) and can lead to instability (He & Raghunathan, 2009) or cause the 
program to fail (White et al., 2011). Hardt et al. (2012) suggested that the ratio of variables to 
cases (with complete data) should not go below 1:3. Van Buuren and Groothuis-Oudshoorn 
(1999) recommended selecting a suitable subset of data that contains no more than 15 – 25 
variables. Enders (2010) suggested that a reasonable goal may be to maximize the squared 
multiple correlation between auxiliary variables and target variables using as few auxiliary 
variables as possible. As variables with low correlations ( .40) have a negligible affect on 
power (Enders, 2010), a good strategy may be to exclude auxiliary variables with low 
correlations and high fractions of missing information. 
Rubin (1987) provided a diagnostic measure that estimates the influence of missing data 
on parameter estimates. Higher fractions of missing information (FMI or 𝛾) represent higher 
uncertainty about estimates (and their resulting conclusions). The estimated FMI can be defined 
as 
𝛾 =
𝑟 + 2/(𝑑𝑓 + 3)
𝑟 + 1
 
where r (the relative increase in variance due to the missing data) is 
𝑟 =
1 + (𝑚−1)𝐵
?̅?
 
and df (based on an approximate t distribution) is 
𝑑𝑓 = (𝑚 − 1)[1 + 𝑟−1] 2 
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Table 2 illustrates the proportional increase in the standard error for different fractions of missing 
data (γ) given the number of imputations (m). The slight decrease in standard error attributable to 
an increase in m suggests that there is little benefit to using m > 5. 
Table 2 
Proportional Increase in Standard Error for m and γ  
        γ    
m 0.10 0.20 0.30 0.40 0.50 0.60 0.70 
3 1.02 1.03 1.05 1.06 1.08 1.10 1.11 
5 1.01 1.02 1.03 1.04 1.05 1.06 1.07 
10 1.00 1.01 1.01 1.02 1.02 1.03 1.03 
20 1.00 1.00 1.01 1.01 1.01 1.01 1.02 
Note: Table was computed using Excel. 
 Determining the number of imputations to generate can be based on the relative 
efficiency (RE) desired. Rubin (1987) showed that the efficiency of an estimate based on m, 
relative to one based on an infinite number of imputations, is 
𝑅𝐸 = (1 +
𝛾
𝑚
)
−1
  
Table 3 
Efficiency as a Function of m and γ 
 
           γ     
m 0.10 0.20 0.30 0.40 0.50 0.60 0.70 0.80 0.90 
3 0.97 0.94 0.91 0.88 0.86 0.83 0.81 0.79 0.77 
5 0.98 0.96 0.94 0.93 0.91 0.89 0.88 0.86 0.85 
10 0.99 0.98 0.97 0.96 0.95 0.94 0.93 0.93 0.92 
20 1.00 0.99 0.99 0.98 0.98 0.97 0.97 0.96 0.96 
Note: Table was computed using Excel. 
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 Table 3 shows the relative efficiency for γ given m. Although the table demonstrates that 
an increase in m can be used to compensate for a large γ, it also shows that modest values of m 
result in parameter estimates that are nearly fully efficient. Because MI enlarges the between-
imputation variance B by a factor 1/m before calculating the total variance in T = U + (1 + m-1) 
B, the classic advice has been that 3 – 5 m is adequate (Rubin, 1987; Schafer, 1997; Schafer & 
Olsen, 1998). Recently, however, there has been some disagreement in the literature. 
Von Hippel (2005) evaluated the impact of different fractions of missing data and found 
that 10 imputations produced a standard error that was 2% larger than an infinite number of 
imputations when a large percentage (40%) of values were missing. Graham, Olchowski and 
Gilreath (2007) investigated the effect of m on the statistical power of a test to detect a small     
(< 0.1) effect and suggested that m > 5 may be needed for small effect sizes, large fractions of 
missing data, and small sample sizes. Bodner (2008) systematically explored the variability of 
the width of the 95% CI, the p value and λ (the proportion of variance attributable to the missing 
data) under various m and recommended that m be based on the percentage of cases that are 
incomplete (a conservative estimate of λ). White, Royston and Wood (2011) concurred with 
Bodner’s (2008) suggestion that m be at least equal to the percentage of incomplete cases. Van 
Buuren and Groothuis-Oudshoorn (1999) suggested setting m to the average percentage of 
missing data but added that “the substantive conclusions are unlikely to change as a result of 
raising m beyond m = 5” (p. 51). Johnson and Young (2011) corroborate Van Buuren’s 
statement. They demonstrated that m = 5 resulted in the same substantive conclusions as m = 25, 
even when auxiliary variables were removed from the model. 
Although the benefits of increasing m beyond 5 are still being debated, imputing a large 
number of datasets may not be practical. Imputing a single dataset with a large model or a large 
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fraction of missing information requires considerable computation time and can prevent 
convergence (Graham, 2012). 
Another consideration when imputing data is whether or not to define constraints. In 
SPSS, constraints can be used to (a) restrict the range of imputed values, (b) exclude variables 
from imputation (e.g., variables with large fractions of missing values and variables that have 
values that are missing by design), and (c) specify rounding rules (see Horton, Lipsitz, & Parzen, 
2003, for caveats). In situations where a subset of cases is believed to be inherently different 
from the rest of the sample, values may be imputed separately using different (split) models 
(Rubin, 1987). Although the role of the variable can be confined, it is not necessary to specify 
whether variables are independent (predictor) or dependent (outcome). Unlike methods that 
exclude cases with missing predictor variables, MI uses observed values to predict missing 
values without regard to each variable’s role in the analysis phase (Enders, 2010). 
After a specified number of iterations is reached, the distribution of parameters governing 
the imputations (e.g., the coefficients in the regression models) should have converged (such that 
the order in which the variables were imputed no longer matters). Plotting the variable means 
and standard deviations at each iteration and imputation can help assess model convergence. 
When convergence is reached, the variance between the sequences will not be larger than the 
variance within the sequences and the streams will be intermingled without showing any definite 
trends (Van Buuren, 2012). Nonconvergence can occur when (a) a large number of variables are 
modeled, (b) a large number of missing values are imputed, (c) analysis variables are left out of 
the imputation model, or (d) the matrix is not positive definite (Graham, 2012). 
 The Analysis Phase. In this phase, each imputed dataset is analyzed using standard 
statistical procedures. As the simulated design for this study is a parallel group RCT, the data 
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will be analyzed using the t test. William Sealy Gosset (Student, 1908) introduced the t 
distribution to allow the probabilities of small samples to be computed when the population 
standard deviation is unknown. Since its introduction, the t test has played an integral role in 
evaluating the efficacy of medical treatments. In his seminal paper, Gosset introduced the t test 
by comparing the number of hours of sleep patients gained when treated with dextro- and laevo- 
forms (optical isomers) of the drug hyoscyamine hydrobromide and concluded that the laevo- 
isomer was more effective. The t test has since become the most used procedure for comparing 
group means in clinical research (Bridge & Sawilowsky, 1999). The t test can be defined as 
𝑡 =
?̅?1 − ?̅?2
√[
𝑠1
2(𝑛1 − 1) + 𝑠2
2(𝑛2 − 1)
𝑛1 + 𝑛2 − 2
] [
𝑛1 + 𝑛2
𝑛1𝑛2
]
 
with 
𝑑𝑓 = 𝑛1 + 𝑛2 − 2 
 Statistical tests, including the t test, are considered robust when they maintain a Type I 
error rate close to the nominal level of significance while maintaining statistical power (Lix, 
Keselman & Keselman, 1996). The t test has two major assumptions: normality and 
homogeneity of variance. 
Although Wilcox (1998) asserted that a violation of the normality assumption could 
result in a substantial loss of power (see his example where a small departure from normality 
reduced the power of the t test from .96 to .28), Zimmerman (1987) found the t test to be scarcely 
affected by nonnormality. Later work by Sawilowsky and Blair (1992) demonstrated that the t 
test produced power rates very similar to the levels expected from normal curve theory 
regardless of population shape, sample size, or effect size. Empirical evidence also demonstrates 
that the t test’s Type I error rate is maintained at the nominal level when sample sizes are 
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approximately equal, sample sizes are fairly large (n > 25 according to Boneau, 1960), and tests 
are two-tailed rather than one-tailed (Boneau, 1960; Huber, 1972; Sawilowsky and Blair, 1992). 
In practice, the normality assumption is far from tenable. Datasets in the medical (Yuan 
& Bentler, 1999) and psychological (Bradley, 1977; Micceri, 1989) literature are likely to be 
skewed and heavy tailed. In a comprehensive study of the distributional characteristics of large 
datasets (almost 70% of the datasets involved 1,000 or more cases), Micceri (1989) found that 
none of the 440 datasets investigated passed the Kolmogrov-Smirnov test of normality. Nearly 
half (49.1%) of the datasets had at least one heavy tail and almost three quarters (71.6%) were 
classified as being moderately to extremely asymmetric (some to the point of being 
exponentially distributed). 
Work by Zimmerman (1987) demonstrated that the t test is relatively robust to violation 
of the homogeneity assumption when samples sizes are equal. If sample sizes differ, then 
inequality of variances can have a pronounced effect on significance levels and on the 
probability of Type I error (Zimmerman, 1987). In this case, the t test either becomes 
conservative or liberal depending upon the relationship between sample size and population 
variance. 
When the t test is performed, SPSS automatically provides the results for Levene’s 
(1960) test for equality of variances. If the test is significant, the variances are not equal. In 
RCTs, the homoscedasticity assumption is often violated because the treatment group is more 
likely to experience greater variability in response to the intervention than the control group.  
The pooling phase. During this phase, the results of the individual analyses are 
combined using mathematical rules developed by Rubin (1987). Most of the statistical 
procedures, available in SPSS, can produce pooled parameter estimates and standard errors for 
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multiply imputed datasets. SPSS pools output at two levels: naïve and univariate. At the naïve 
level only the pooled parameter is available. At the univariate level, the pooled parameter and its 
standard error, test statistic, effective degrees of freedom, p-value, CI, and pooling diagnostics 
(FMI, RE, relative increase in variance) are available. The t test procedure, in SPSS, supports 
mean pooling at the univariate level and n pooling at naïve level. Statistics that are not estimators 
(e.g., likelihood ratio, chi-square, p-value) cannot be combined and SPSS will not allow those 
analyses to pool. According to notation in IBM SPSS 20 Algorithms (2011), the final estimate of 
𝑄 is simply the average of the individual point estimates and can be defined as 
?̅? =
1
𝑚
∑ ?̂?𝑖
𝑚
𝑖=1
 
 
where ?̂? is the parameter estimate from the ith dataset and m is the number of imputations. 
The estimated total variance is 
𝑇 = ?̅? + (1 +
1
𝑚
 ) 𝐵 
where 𝐵 (the between imputation variance) is 
𝐵 =
1
𝑚 − 1
∑(?̂?𝑖 − ?̅?)
𝑚
𝑖=1
(?̂?𝑖 − ?̅?)′ 
and ?̅? (the within imputation variance) is 
?̅? =
1
𝑚
∑ 𝑈𝑖
𝑚
𝑖=1
 
with 
𝑑𝑓 = (𝑚 − 1)[1 + 𝑟−1] 2 
 Unlike other statistical contexts, the df in MI is not affected by n. Barnard and Rubin 
(1999) noted that the above df equation can produce values that are larger than the df in the 
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complete data and developed an adapted version for small samples. There is a void in the MI 
literature (as well as the SPSS documentation) that discusses this solution and it is not clear 
whether SPSS makes this adjustment.  
It should be noted that missing elements in 
      {?̂?𝑖, 𝑈𝑖}  𝑖=1
𝑚  
are excluded from the calculations.  
The p-value for testing H0: Q = Q is 
𝑝 = Pr (𝐹𝑘,𝑣 ≥ 𝐹) 
where 
𝐹 =
1
𝑘
(?̅? − 𝑄0)
𝑇?̃? − (?̅? − 𝑄0) 
𝑘 = 𝑟𝑎𝑛𝑘(?̃?) 
𝑣 = ?̃? 
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CHAPTER 3 METHODS 
 The National Academy of Science (2010) identified numerous high priority areas for 
missing data research that are echoed in the literature. Several of those areas will be addressed by 
systematically investigating the impact of MI on the rejection rate of the independent samples t 
test under a range of conditions that reflect the interplay of complexities that arise when 
analyzing differences between treatment arms in RCTs. More specifically, a factorial design that 
includes eight sample sizes, five effect sizes, three fractions of missing data, three distributions, 
and two alpha levels will be used to determine if MI impacts Type II error in parallel group 
RCTs. Fully crossed, this design represents 720 distinct conditions.  
Although enormous amounts of computational resources are required to conduct MI 
simulations (see Hardt et al., 2012, for an example of a simulation of 100 cases that required 
more than 200 hours of computing time on a 6 physical core PC optimized for simulations), each 
of the 720 conditions will be replicated 1,000 times.  
Data Generation 
 Two samples (X1, Y) of sizes (n1, n2) = (10, 10), (20, 20), (30, 30), (40, 40), (60, 60), (10, 
30), (20, 60), (30, 90) will be drawn from the Normal (0, 1), Chi-square (df = 1) and t (df = 3) 
distributions. The samples will simulate a parallel group RCT with X1 serving as the control 
group and Y serving as the treatment group. As pilot trials can have samples as small as n = 20 
(Barnes, Lindborg & Seaman, 2006), the eight sample sizes proposed are intended to reflect the 
small balanced and unbalanced designs likely to occur in clinical practice. Several of the sample 
sizes also mirror those used in past simulation studies that investigated the robustness of the t test 
(e.g., Sawilowsky & Blair, 1992; Sawilowsky & Hillman, 1992). A third variable (X2) with a .50 
correlation with Y will serve as an auxiliary variable in the imputation model.  
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 The control sample (X1) will be generated using the distribution random variable function 
in SPSS (version 22). The treatment sample (Y) and auxiliary variable (X2) will be generated via 
algorithms presented by Headrick and Sawilowsky (2000) to solve the Fleishman (1978) 
equation for a .50 correlation. The Fleishman method was chosen because it was shown to 
generate average values of intercorrelations closer to population parameters than competing 
procedures for skewed distributions and small sample sizes (Headrick & Sawilowsky, 2000).  
Table 4 
Solutions to the Fleishman Equation 
Distribution μ σ γ1 γ2 a b d 
Normal Distribution 0 1 0 0 0 1 0 
Chi-square (df=1) 1 √2 √8 12 -.5207 .6146 .02007 
t (df=3) 0 √3 0 17 0 .3938 .17130 
Note. γ1 = skew, γ2 = kurtosis 
First, the constants for each distribution (presented in Table 4) will be used to solve for rxy where 
𝑟𝑥𝑦 = 𝑟
2(𝑏2 + 6𝑏𝑑 + 9𝑑2 + 2𝑎2𝑟2 + 6𝑑2𝑟4) 
Then, the SPSS random variable function will be used to generate three random normal variates 
(Z1, Z2, Z3) which will be used to solve for Xa and Ya where 
𝑋𝑎 = 𝑟(𝑍1) + (𝑍2)√1 − 𝑟2  
and  
𝑌𝑎 = 𝑟(𝑍1) + (𝑍3)√1 − 𝑟2 
After which, Xa and Ya will be used to solve for Xb and Yb where 
𝑋𝑏 = 𝑎 + 𝑏𝑋1 + (−𝑎)𝑋1
2 + 𝑑𝑋1
3 
and 
𝑌𝑏 = 𝑎 + 𝑏𝑌1 + (−𝑎)𝑌1
2 + 𝑑𝑌1
3 
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Finally, Xb and Yb will be transformed back into their distribution metric using 
𝑋𝑜 = 𝜎𝑋 + 𝜇 
and 
𝑌𝑜 = 𝜎𝑋 + 𝜇 
 A treatment effect will be will simulated by applying the algorithm YT = YO + k where k 
is equal to a constant treatment effect and  reflects the standard deviation of the distribution 
under investigation (Table 4). Proposed ES include small (0.2σ), medium (0.5σ), and large (0.8σ) 
as suggested by Cohen (1988) as well as very large (1.2σ) and huge (2.0σ) as proposed by 
Sawilowsky (2009). Despite warnings from Cohen (1988) about these values becoming de facto 
standards for research, they are proposed to facilitate comparisons across studies and allow for 
meta-analysis.  
Table 5 
 
Number of Values Treated as Missing 
 
                                       Sample Size (YT) 
Fraction of Missing Data 10 20 30 40 60 90 
0.10  1   2   3   4   6   9 
0.30  3   6   9 12 18 27 
0.50  5 10 15 20 30 45 
 
 Table 5 presents the number of values (for variable YT) that will be defined as missing. 
To simulate a monotone missing data pattern, 10%, 30%, or 50% of the YT values will be deleted 
using random uniform numbers. If the rank of the generated number is equal to or less than the 
percentage specified, the data point will be deleted.  
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Parameters 
Missing values will be imputed using SPSS version 22. Parameters will be set to 10 
iterations and m = 5 which represent the defaults in SPSS. According to Van Buuren (2012), the 
software defaults are often reasonable. The defaults were also chosen because they are most 
likely to be used by practitioners unfamiliar with MI. The analyses will be conducted using a 
two-tailed independent samples t test. The combining step will be performed by SPSS using the 
formulas presented in the literature review. The Python 2.7 programming language will be used 
to repeat the entire process 1,000 times for each combination of factor levels and report the 
rejection rates for the .01 and .05 alpha levels 
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CHAPTER 4 RESULTS 
 Tables 6 – 10 present the number of rejections out of 1,000 for the Normal distribution 
under varying sample sizes, effect sizes, fractions of data imputed, and alpha. The Normal 
distribution has two parameters: a location parameter (μ) and a scale parameter (σ). The 
distribution was simulated using a location parameter of 0 and a scale parameter of 1. 
    
 
Figure 6. Normal distribution (0, 1). Created using SPSS syntax. 
 
The probability density function for the Normal distribution (Figure 6) is 
1
𝜎√2𝜋
𝑒 −
(𝑋−𝜇)2
2𝜎2  
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Table 6 
 
Small (0.2σ) Treatment Effect Rejection Rates for the Normal Distribution  
 
  α = .01  α = .05 
  Fraction of data imputed  Fraction of data imputed 
n1, n2  0.100 0.300 0.500  0.100 0.300 0.500 
10, 10  0.031 0.034 0.023  0.068 0.082 0.064 
20, 20  0.028 0.023 0.020  0.103 0.104 0.095 
30, 30  0.036 0.032 0.023  0.138 0.107 0.101 
40, 40  0.042 0.043 0.034  0.165 0.139 0.116 
60, 60  0.067 0.058 0.056  0.195 0.164 0.120 
10, 30  0.036 0.019 0.025  0.067 0.084 0.076 
20, 60  0.027 0.034 0.039  0.148 0.126 0.100 
30, 90  0.048 0.045 0.050  0.137 0.152 0.150 
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Table 7 
 
Medium (0.5σ) Treatment Effect Rejection Rates for the Normal Distribution 
 
  α = .01  α = .05 
  Fraction of data imputed  Fraction of data imputed 
n1, n2  0.100 0.300 0.500  0.100 0.300 0.500 
10, 10  0.085 0.067 0.065  0.193 0.179 0.172 
20, 20  0.174 0.151 0.107  0.375 0.316 0.251 
30, 30  0.231 0.221 0.139  0.429 0.426 0.336 
40, 40  0.364 0.264 0.222  0.558 0.535 0.449 
60, 60  0.528 0.441 0.350  0.759 0.725 0.599 
10, 30  0.114 0.118 0.093  0.266 0.267 0.217 
20, 60  0.266 0.235 0.172  0.481 0.449 0.386 
30, 90  0.406 0.346 0.309  0.654 0.588 0.576 
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Table 8 
 
Large (0.8σ) Treatment Effect Rejection Rates for the Normal Distribution  
 
  α = .01  α = .05 
  Fraction of data imputed  Fraction of data imputed 
n1, n2  0.100 0.300 0.500  0.100 0.300 0.500 
10, 10  0.235 0.183 0.120  0.419 0.355 0.290 
20, 20  0.483 0.400 0.284  0.700 0.604 0.514 
30, 30  0.684 0.570 0.446  0.839 0.800 0.668 
40, 40  0.804 0.740 0.585  0.939 0.882 0.823 
60, 60  0.950 0.894 0.788  0.991 0.966 0.938 
10, 30  0.348 0.303 0.281  0.582 0.562 0.474 
20, 60  0.672 0.637 0.551  0.863 0.842 0.771 
30, 90  0.870 0.842 0.757  0.966 0.956 0.918 
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Table 9 
 
Very Large (1.2σ) Treatment Effect Rejection Rates for the Normal Distribution  
 
  α = .01  α = .05 
  Fraction of data imputed  Fraction of data imputed 
n1, n2  0.100 0.300 0.500  0.100 0.300 0.500 
10, 10  0.516 0.432 0.320  0.720 0.675 0.555 
20, 20  0.878 0.811 0.623  0.954 0.925 0.834 
30, 30  0.968 0.923 0.841  0.996 0.984 0.958 
40, 40  0.997 0.985 0.935  0.999 0.998 0.991 
60, 60  1.000 0.999 0.993  1.000 1.000 1.000 
10, 30  0.723 0.692 0.603  0.902 0.862 0.794 
20, 60  0.963 0.952 0.925  0.994 0.991 0.968 
30, 90  0.999 0.997 0.991  1.000 1.000 0.997 
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Table 10  
 
Huge (2.0σ) Treatment Effect Rejection Rates for the Normal Distribution 
 
  α = .01  α = .05 
  Fraction of data imputed  Fraction of data imputed 
n1, n2  0.100 0.300 0.500  0.100 0.300 0.500 
10, 10  0.950 0.887 0.764  0.991 0.967 0.904 
20, 20  0.999 0.996 0.979  1.000 1.000 0.999 
30, 30  1.000 1.000 0.996  1.000 1.000 1.000 
40, 40  1.000 1.000 1.000  1.000 1.000 1.000 
60, 60  1.000 1.000 1.000  1.000 1.000 1.000 
10, 30  0.996 0.997 0.970  1.000 1.000 0.998 
20, 60  1.000 1.000 1.000  1.000 1.000 1.000 
30, 90  1.000 1.000 1.000  1.000 1.000 1.000 
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 Tables 11 – 15 present the number of rejections out of 1,000 for the Chi-square (χ2) 
distribution under varying sample sizes, effect sizes, fractions of data imputed, and alpha. The 
Chi-square distribution has a single parameter: df. The distribution was simulated using df = 1 
 
 
Figure 7. χ2 distribution (df = 1). Created using SPSS syntax. 
 
The probability density function for the χ2 distribution (Figure 7) is 
1
2
𝑘
2 Γ (
𝑘
2)
𝑥
𝑘
2−1𝑒−
𝑥
2 
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Table 11 
 
Small (0.2σ) Treatment Effect Rejection Rates for the χ2 Distribution (df=1) 
 
  α = .01  α = .05 
  Fraction of data imputed  Fraction of data imputed 
n1, n2  0.100 0.300 0.500  0.100 0.300 0.500 
10, 10  0.034 0.024 0.017  0.093 0.085 0.076 
20, 20  0.039 0.033 0.015  0.105 0.117 0.106 
30, 30  0.040 0.046 0.046  0.152 0.118 0.122 
40, 40  0.053 0.053 0.030  0.160 0.139 0.124 
60, 60  0.079 0.067 0.063  0.203 0.167 0.165 
10, 30  0.022 0.025 0.017  0.104 0.089 0.084 
20, 60  0.033 0.037 0.027  0.134 0.158 0.114 
30, 90  0.053 0.054 0.045  0.192 0.162 0.133 
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Table 12 
 
Medium (0.5σ) Treatment Effect Rejection Rates for the χ2 Distribution (df=1) 
 
  α = .01  α = .05 
  Fraction of data imputed  Fraction of data imputed 
n1, n2  0.100 0.300 0.500  0.100 0.300 0.500 
10, 10  0.144 0.115 0.094  0.278 0.250 0.222 
20, 20  0.214 0.197 0.168  0.413 0.387 0.316 
30, 30  0.317 0.251 0.195  0.515 0.454 0.394 
40, 40  0.386 0.361 0.257  0.631 0.569 0.463 
60, 60  0.547 0.493 0.372  0.768 0.724 0.609 
10, 30  0.147 0.173 0.158  0.354 0.352 0.289 
20, 60  0.295 0.281 0.255  0.537 0.508 0.468 
30, 90  0.455 0.401 0.366  0.681 0.611 0.580 
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Table 13 
 
Large (0.8σ) Treatment Effect Rejection Rates for the χ2 Distribution (df=1) 
 
  α = .01  α = .05 
  Fraction of data imputed  Fraction of data imputed 
n1, n2  0.100 0.300 0.500  0.100 0.300 0.500 
10, 10  0.325 0.306 0.212  0.520 0.484 0.403 
20, 20  0.543 0.470 0.365  0.712 0.664 0.580 
30, 30  0.709 0.624 0.469  0.843 0.804 0.705 
40, 40  0.819 0.726 0.643  0.914 0.894 0.817 
60, 60  0.937 0.898 0.796  0.977 0.957 0.920 
10, 30  0.448 0.411 0.375  0.651 0.620 0.564 
20, 60  0.683 0.678 0.609  0.864 0.834 0.796 
30, 90  0.856 0.853 0.769  0.947 0.925 0.916 
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Table 14 
 
Very Large (1.2σ) Treatment Effect Rejection Rates for the χ2 Distribution (df=1) 
 
  α = .01  α = .05 
  Fraction of data imputed  Fraction of data imputed 
n1, n2  0.100 0.300 0.500  0.100 0.300 0.500 
10, 10  0.636 0.552 0.463  0.754 0.708 0.623 
20, 20  0.860 0.797 0.665  0.929 0.894 0.841 
30, 30  0.948 0.897 0.821  0.984 0.971 0.950 
40, 40  0.991 0.964 0.914  0.994 0.990 0.984 
60, 60  0.999 0.994 0.980  1.000 0.999 0.999 
10, 30  0.759 0.723 0.663  0.900 0.858 0.830 
20, 60  0.925 0.936 0.890  0.987 0.982 0.969 
30, 90  0.987 0.988 0.978  0.997 0.996 0.995 
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Table 15 
 
Huge (2.0σ) Treatment Effect Rejection Rates for the χ2 Distribution (df=1) 
 
  α = .01  α = .05 
  Fraction of data imputed  Fraction of data imputed 
n1, n2  0.100 0.300 0.500  0.100 0.300 0.500 
10, 10  0.899 0.865 0.765  0.966 0.947 0.888 
20, 20  0.992 0.982 0.953  0.995 0.998 0.992 
30, 30  1.000 0.999 0.983  1.000 0.999 1.000 
40, 40  1.000 1.000 1.000  1.000 1.000 1.000 
60, 60  1.000 1.000 1.000  1.000 1.000 1.000 
10, 30  0.976 0.955 0.923  0.991 0.992 0.981 
20, 60  0.999 0.999 0.997  0.999 1.000 0.999 
30, 90  1.000 1.000 1.000  1.000 1.000 1.000 
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 Tables 16 – 20 present the number of rejections out of 1,000 for the t distribution under 
varying sample sizes, effect sizes, fractions of data imputed, and alpha. The t distribution has a 
single parameter: df. The distribution was simulated using df = 3. 
 
 
Figure 8. t distribution (df = 3). Created using SPSS syntax. 
 
The probability density function for the t distribution (Figure 8) is 
Γ (
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Table 16 
 
Small (0.2σ) Treatment Effect Rejection Rates for the t Distribution (df=3) 
 
  α = .01  α = .05 
  Fraction of data imputed  Fraction of data imputed 
n1, n2  0.100 0.300 0.500  0.100 0.300 0.500 
10, 10  0.026 0.024 0.021  0.098 0.086 0.078 
20, 20  0.047 0.022 0.025  0.117 0.106 0.095 
30, 30  0.026 0.029 0.035  0.139 0.114 0.123 
40, 40  0.060 0.044 0.030  0.153 0.145 0.125 
60, 60  0.059 0.076 0.063  0.211 0.183 0.156 
10, 30  0.027 0.021 0.016  0.112 0.107 0.087 
20, 60  0.035 0.041 0.035  0.137 0.118 0.115 
30, 90  0.066 0.047 0.064  0.168 0.163 0.163 
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Table 17 
 
Medium (0.5σ) Treatment Effect Rejection Rates for the t Distribution (df=3) 
 
  α = .01  α = .05 
  Fraction of data imputed  Fraction of data imputed 
n1, n2  0.100 0.300 0.500  0.100 0.300 0.500 
10, 10  0.138 0.125 0.090  0.311 0.290 0.211 
20, 20  0.224 0.178 0.150  0.411 0.395 0.332 
30, 30  0.318 0.268 0.202  0.543 0.515 0.421 
40, 40  0.384 0.363 0.288  0.624 0.612 0.511 
60, 60  0.575 0.508 0.402  0.760 0.725 0.640 
10, 30  0.171 0.151 0.147  0.329 0.306 0.286 
20, 60  0.289 0.290 0.237  0.491 0.500 0.469 
30, 90  0.439 0.432 0.397  0.669 0.620 0.596 
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Table 18 
 
Large (0.8σ) Treatment Effect Rejection Rates for the t Distribution (df=3) 
 
  α = .01  α = .05 
  Fraction of data imputed  Fraction of data imputed 
n1, n2  0.100 0.300 0.500  0.100 0.300 0.500 
10, 10  0.353 0.298 0.259  0.564 0.480 0.393 
20, 20  0.555 0.514 0.397  0.749 0.698 0.599 
30, 30  0.716 0.642 0.514  0.856 0.798 0.737 
40, 40  0.805 0.749 0.610  0.919 0.887 0.813 
60, 60  0.921 0.887 0.803  0.970 0.955 0.927 
10, 30  0.455 0.430 0.368  0.624 0.602 0.567 
20, 60  0.707 0.673 0.593  0.837 0.834 0.780 
30, 90  0.881 0.822 0.772  0.954 0.910 0.924 
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Table 19 
 
Very Large (1.2σ) Treatment Effect Rejection Rates for the t Distribution (df=3) 
 
  α = .01  α = .05 
  Fraction of data imputed  Fraction of data imputed 
n1, n2  0.100 0.300 0.500  0.100 0.300 0.500 
10, 10  0.643 0.545 0.450  0.798 0.740 0.657 
20, 20  0.852 0.770 0.687  0.940 0.910 0.877 
30, 30  0.935 0.908 0.838  0.979 0.973 0.940 
40, 40  0.975 0.970 0.903  0.999 0.991 0.969 
60, 60  0.999 0.997 0.978  1.000 1.000 0.997 
10, 30  0.785 0.743 0.703  0.894 0.859 0.834 
20, 60  0.956 0.945 0.904  0.985 0.983 0.969 
30, 90  0.993 0.986 0.975  0.998 0.996 0.994 
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Table 20 
 
Huge (2.0σ) Treatment Effect Rejection Rates for the t Distribution (df=3) 
 
  α = .01  α = .05 
  Fraction of data imputed  Fraction of data imputed 
n1, n2  0.100 0.300 0.500  0.100 0.300 0.500 
10, 10  0.905 0.871 0.796  0.949 0.929 0.911 
20, 20  0.986 0.990 0.947  0.998 0.992 0.980 
30, 30  0.998 0.996 0.988  1.000 1.000 0.998 
40, 40  1.000 0.999 0.998  1.000 1.000 1.000 
60, 60  1.000 1.000 1.000  1.000 1.000 1.000 
10, 30  0.971 0.963 0.939  0.988 0.986 0.974 
20, 60  1.000 0.998 0.997  1.000 0.998 0.997 
30, 90  1.000 1.000 0.999  1.000 1.000 1.000 
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CHAPTER 5 DISCUSSION 
 Table 21 was constructed to serve as a benchmark to separate the effects of power theory 
from those induced by MI. It was created by drawing two samples (X1, X2) of sizes (n1, n2) from 
the Normal distribution, adding the stated treatment effect to X2, conducting a two-tailed 
independent samples t test, and advancing a counter if the test was significant at the given alpha 
level. The procedure was repeated 1,000 times for each combination of factor levels. The results 
show the rejection rates that would be expected under normal power theory and demonstrate the 
power advantage of larger (balanced) samples, larger effect sizes, and a less conservative alpha 
level.  
Table 21 
 
Rejection Rates for the Nonimputed Normal Distribution 
 
  α = .01  α = .05 
  Effect Size  Effect Size 
n1, n2  0.2σ 0.5σ 0.8σ 1.2σ 2.0σ  0.2σ 0.5σ 0.8σ 1.2σ 2.0σ 
10, 10  0.018 0.049 0.171 0.440 0.927  0.059 0.190 0.385 0.725 0.987 
20, 20  0.019 0.152 0.409 0.871 0.999  0.101 0.327 0.701 0.961 1.000 
30, 30  0.023 0.255 0.680 0.972 1.000  0.123 0.478 0.850 0.995 1.000 
40, 40  0.043 0.337 0.845 0.993 1.000  0.154 0.584 0.949 1.000 1.000 
60, 60  0.069 0.563 0.960 1.000 1.000  0.168 0.774 0.994 1.000 1.000 
10, 30  0.021 0.098 0.301 0.716 0.996  0.076 0.262 0.558 0.897 0.999 
20, 60  0.023 0.264 0.641 0.971 1.000  0.129 0.486 0.860 0.991 1.000 
30, 90  0.047 0.408 0.878 0.998 1.000  0.143 0.662 0.973 1.000 1.000 
 
 A small (0.2σ) difference between treatment arms was virtually undetectable (< 7%) at 
the .01 alpha level and marginally detectable (< 17%) at the .05 alpha level. Although clinicians 
would hope that a medium (0.5σ) treatment effect would be detected with a relatively small 
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sample, at the .01 alpha level, a sample size of 30, 30 yielded a one-in-four (.255) chance of 
rejection. At the .05 alpha level, clinicians had slightly less than a 50-50 (.478) chance of 
detecting a difference between treatment arms with the same 30, 30 sample size. Unbalanced 
designs were less powerful; a sample size of 20, 60 was necessary to achieve the same one-in-
four (.264) results at alpha .01 and one-in-two (.486) results at alpha .05. A large (0.8σ) 
difference between treatment arms was detectable at Cohen’s recommended .80 (β = .20) level 
once the sample size for balanced designs reached 40, 40 at alpha .01 and 30, 30 at alpha .05. 
Unbalanced designs reached the recommended power level once the sample size reached 30, 90 
at alpha .01 and 20, 60 at alpha .05. A very large (1.2σ) treatment effect was detectable at the 
recommended .80 power level for all of the sample sizes save for the 10, 10 and 10, 30 levels at 
alpha .01 and the 10, 10 level at alpha .05. A huge difference between treatment arms was 
detectable at near maximum power for all of the sample sizes tested at both alpha levels. 
 The rejection rates presented in Tables 6 – 20 can be used to aid clinicians in determining 
the power that they can expect to achieve given a specific distribution, effect size, sample size, 
fraction of data imputed, and alpha. The results show that the rejection rates for imputed data 
follow the trends that would be expected under normal power theory regardless of distribution. 
There was a positive relationship between effect size and rejection rates with minimal power at 
the small (0.2σ) effect size level and near maximum power at the huge (2.0σ) effect size level. 
As expected, there was a positive relationship between sample size and rejection rates with 
balanced samples being more powerful than unbalanced samples. Power was also higher at the 
less conservative .05 alpha level.  
 Tables 22 – 26 illustrate the impact of distribution shape on rejection rates by presenting 
the range of rejection rates (the distribution with the highest rejection rate minus the distribution 
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with the lowest rejection rate) for the three distributions under investigation. The largest 
differences tended to occur at the smallest balanced (10, 10) and unbalanced (10, 30) sample size 
levels. The Normal distribution tended to reject at a lower rate than the Chi-square and t 
distributions at the medium (0.5σ) and large (0.8σ) effect size levels, but rejected at a higher rate 
at the very large (1.2σ) effect size level. 
 With a small (0.2σ) treatment effect, the largest difference at the .01 alpha level was 2.3 
percentage points and occurred at the 30, 30 sample size level with 50% of the data imputed 
between the Normal (.023) and Chi-square (.046) distributions. The largest difference at alpha 
.05 was 5.5% and occurred at the 30, 90 sample size level with 10% of the data imputed between 
the Normal (.137) and Chi-square (.192) distributions.  
 With a medium (0.5σ) treatment effect, the largest difference at the .01 alpha level was 
9.9 percentage points and occurred at the 40, 40 sample size level with 30% of the data imputed 
between the Normal (.264) and t (.363) distributions. The largest difference at the .05 alpha level 
was 11.8% and occurred at the 10, 10 sample size level with 10% of the data imputed between 
the Normal distribution (.193) and the t distribution (.311).  
 With a large (0.8σ) treatment effect, the largest difference at the .01 alpha level was 
13.9% and occurred at the 10, 10 sample size level with 50% of the data imputed between the 
Normal (.120) and t (.259) distributions. At the .05 alpha level, the largest difference was 14.5% 
and occurred at the 10, 10 sample size level with 10% of the data imputed between the Normal 
distribution (.419) and the t distribution (.564). Excluding the 10, 10 and 20, 20 balanced sample 
size levels and the 10, 30 unbalanced sample size level reduced the largest difference at alpha .01 
to 7.2% and the largest difference at alpha .05 to 6.9%.  
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Table 22 
Range of Distribution Rejection Rates for a Small (0.2σ) Treatment Effect  
 
  α = .01  α = .05 
  Percentage of data imputed  Percentage of data imputed 
n1, n2  10% 30% 50%  10% 30% 50% 
10, 10   0.8   1.0  0.6   3.0  0.4  1.4 
20, 20   1.9  1.1  1.0   1.4  1.3  1.1 
30, 30   1.4  1.7  2.3   1.4  1.1  2.2 
40, 40   1.8  1.0  0.4   1.2  0.6  0.9 
60, 60   2.0  1.8  0.7   1.6  1.9  4.5 
10, 30   1.4  0.6  0.9   4.5  2.3  1.1 
20, 60   0.8  0.7  1.2   1.4  4.0  1.5 
30, 90   1.8  0.9  1.9   5.5  1.1  3.0 
 
Table 23 
Range of Distribution Rejection Rates for a Medium (0.5σ) Treatment Effect 
 
  α = .01  α = .05 
  Percentage of data imputed  Percentage of data imputed 
n1, n2  10% 30% 50%  10% 30% 50% 
10, 10   5.9   5.8  2.9     11.8    11.1  5.0 
20, 20   5.0  4.6  6.1   3.8  7.9  8.1 
30, 30   8.7  4.7  6.3     11.4  8.9  8.5 
40, 40   2.2  9.9  6.6   7.3  7.7  6.2 
60, 60   4.7  6.7  5.2   0.9  0.1  4.1 
10, 30   5.7  5.5  6.5   8.8  8.5  7.2 
20, 60   2.9  5.5  8.3   5.6  5.9  8.3 
30, 90   4.9  8.6  8.8   2.7  3.2  2.0 
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Table 24 
Range of Distribution Rejection Rates for a Large (0.8σ) Treatment Effect 
 
  α = .01  α = .05 
  Percentage of data imputed  Percentage of data imputed 
n1, n2  10% 30% 50%  10% 30% 50% 
10, 10      11.8 12.3    13.9      14.5     12.9    11.3 
20, 20        7.2 11.4 11.3   4.9  9.4  8.5 
30, 30        3.2  7.2  6.8   1.7  0.6  6.9 
40, 40        1.5  2.3  5.8   2.5  1.2  1.0 
60, 60        2.9  1.1  1.5   2.1  1.1  1.8 
10, 30      10.7 12.7  9.4   6.9  5.8  9.3 
20, 60        3.5  4.1  5.8   2.7  0.8  2.5 
30, 90        2.5  3.1  1.5   1.9  4.6  0.8 
 
Table 25 
Range of Distribution Rejection Rates for a Very Large (1.2σ) Treatment Effect 
 
  α = .01  α = .05 
  Percentage of data imputed  Percentage of data imputed 
n1, n2  10% 30% 50%  10% 30% 50% 
10, 10     12.7    12.0    14.3  7.8   6.5    10.2 
20, 20       2.6      4.1      6.4   2.5  3.1  4.3 
30, 30       3.3      2.6      2.0   1.7  1.3  1.8 
40, 40       2.2      2.1      3.2   0.5  0.8  2.2 
60, 60       0.1      0.5      1.5   0.0  0.1  0.3 
10, 30       6.2      5.1    10.0   0.8  0.4  4.0 
20, 60       3.8      1.6      3.5   0.9  0.9  0.1 
30, 90       1.2      1.1      1.6   0.3  0.4  0.3 
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Table 26 
Range of Distribution Rejection Rates for a Huge (2.0σ) Treatment Effect 
 
  α = .01  α = .05 
  Percentage of data imputed  Percentage of data imputed 
n1, n2  10% 30% 50%  10% 30% 50% 
10, 10  5.1 2.2 3.2  4.2 3.8 2.3 
20, 20  1.3 1.4 3.2  0.5 0.8 1.9 
30, 30  0.2 0.4 1.3  0.0 0.1 0.2 
40, 40  0.0 0.1 0.2  0.0 0.0 0.0 
60, 60  0.0 0.0 0.0  0.0 0.0 0.0 
10, 30  2.5 4.2 4.7  1.2 1.4 2.4 
20, 60  0.1 0.2 0.3  0.1 0.2 0.3 
30, 90  0.0 0.0 0.1  0.0 0.0 0.0 
 
 With a very large (1.2σ) treatment effect, the largest difference at the .01 alpha level was 
14.3% and occurred at the 10, 10 sample size level with 50% of the data imputed between the 
Normal distribution (.320) and the Chi-square distribution (.463). At the .05 alpha level, the 
largest difference was 10.2% and occurred at the 10, 10 sample size level with 50% of the data 
imputed between the Normal (.555) and t (.657) distributions. Excluding the 10, 10 and 20, 20 
balanced sample size levels and the 10, 30 unbalanced sample size level reduced the largest 
difference at alpha .01 to 3.8% and the largest difference at alpha .05 to 2.2%. 
 With a huge (2.0σ) treatment effect, the largest difference at the .01 alpha level was 5.1% 
and occurred at the 10, 10 sample size level with 10% of the data imputed between the Chi-
square (.899) and Normal (.950) distributions. At the .05 alpha level, the largest difference was 
4.2% and occurred at the 10, 10 sample size level with 10% of the data imputed between the t 
(.949) and Normal (.991) distributions. Excluding the 10, 10 and 20, 20 balanced sample size 
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levels and the 10, 30 unbalanced sample size level virtually eliminated any differences between 
the distributions. 
Tables 27 – 41 present the change in the rejection rate as a result of the change in the 
percentage of data imputed (PDI) for the given distribution, effect size, sample size and alpha. 
The results show that although statistical power decreased (or Type II error increased) as the PDI 
increased, the magnitude of the power loss was dependent upon effect size. As effect size 
increased, the change in rejection rate (as a function of the change in PDI) increased until the 
effect size reached the large (1.2) level at which point the trend reversed itself. Had the study 
not included Sawilowsky’s (2009) very large and huge effect size levels, this finding would have 
been missed. 
 With a small (0.2σ) treatment effect (Tables 27 – 29), as the PDI increased from 10% to 
30%, the loss of power was 2.5% or less at alpha .01 and 3.6% or less at alpha .05 regardless of 
sample size and distribution. As the PDI increased from 30% to 50%, the loss of power was 
2.3% or less at alpha .01 and 4.4% or less at alpha .05 regardless of sample size and distribution. 
As the PDI increased from 10% to 50%, the loss of power was 3% or less at alpha .01 and 7.5% 
or less at alpha .05 regardless of sample size and distribution.  
With a medium (0.5σ) treatment effect (Tables 30 – 32), as the PDI increased from 10% 
to 30%, the loss of power was 10% or less regardless of sample size for the Normal distribution 
and 6.7% or less regardless of sample size for the Chi-square and t distributions at alpha .01. At 
the .05 alpha level, the loss of power was 7% or less regardless of sample size and distribution. 
As the PDI increased from 30% to 50%, the loss of power was 12.6% or less regardless of 
sample size, distribution, and alpha. As the PDI increased from 10% to 50%, the loss of power 
was 17.8% or less regardless of sample size, distribution, and alpha. 
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Table 27 
Impact of PDI on Normal Distribution, Small (0.2σ) Effect Size Rejection Rates 
  α = .01  α = .05 
  % Change in Rejection Rate  % Change in Rejection Rate 
n1, n2  10-30% 30-50% 10-50%  10-30% 30-50% 10-50% 
10, 10   0.3 -1.1 -0.8    1.4 -1.8 -0.4 
20, 20  -0.5 -0.3 -0.8    0.1 -0.9 -0.8 
30, 30  -0.4 -0.9 -1.3   -3.1 -0.6 -3.7 
40, 40   0.1 -0.9 -0.8   -2.6 -2.3 -4.9 
60, 60  -0.9 -0.2 -1.1   -3.1 -4.4 -7.5 
10, 30  -1.7  0.6 -1.1    1.7 -0.8  0.9 
20, 60   0.7  0.5  1.2   -2.2 -2.6 -4.8 
30, 90  -0.3  0.5  0.2    1.5 -0.2  1.3 
 
Table 28 
Impact of PDI on X2 Distribution, Small (0.2σ) Effect Size Rejection Rates 
  α = .01  α = .05 
  % Change in Rejection Rate  % Change in Rejection Rate 
n1, n2  10-30% 30-50% 10-50%  10-30% 30-50% 10-50% 
10, 10  -1.0 -0.7 -1.7   -0.8 -0.9 -1.7 
20, 20  -0.6 -1.8 -2.4    1.2 -1.1  0.1 
30, 30   0.6  0.0  0.6   -3.4  0.4 -3.0 
40, 40   0.0 -2.3 -2.3   -2.1 -1.5 -3.6 
60, 60  -1.2 -0.4 -1.6   -3.6 -0.2 -3.8 
10, 30   0.3 -0.8 -0.5   -1.5 -0.5 -2.0 
20, 60   0.4 -1.0 -0.6    2.4 -4.4 -2.0 
30, 90   0.1 -0.9 -0.8   -3.0 -2.9 -5.9 
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Table 29 
Impact of PDI on t Distribution, Small (0.2σ) Effect Size Rejection Rates  
  α = .01  α = .05 
  % Change in Rejection Rate  % Change in Rejection Rate 
n1, n2  10-30% 30-50% 10-50%  10-30% 30-50% 10-50% 
10, 10  -0.2 -0.3 -0.5   -1.2 -0.8 -2.0 
20, 20  -2.5  0.3 -2.2   -1.1 -1.1 -2.2 
30, 30   0.3  0.6  0.9   -2.5  0.9 -1.6 
40, 40  -1.6 -1.4 -3.0   -0.8 -2.0 -2.8 
60, 60   1.7 -1.3  0.4   -2.8 -2.7 -5.5 
10, 30  -0.6 -0.5 -1.1   -0.5 -2.0 -2.5 
20, 60   0.6 -0.6  0.0   -1.9 -0.3 -2.2 
30, 90  -1.9  1.7 -0.2   -0.5  0.0 -0.5 
 
Table 30 
Impact of PDI on Normal Distribution, Medium (0.5σ) Effect Size Rejection Rates 
  α = .01  α = .05 
  % Change in Rejection Rate  % Change in Rejection Rate 
n1, n2  10-30% 30-50% 10-50%  10-30% 30-50% 10-50% 
10, 10    -1.8 -0.2   -2.0   -1.4   -0.7   -2.1 
20, 20    -2.3 -4.4   -6.7   -5.9   -6.5 -12.4 
30, 30    -1.0 -8.2   -9.2   -0.3   -9.0   -9.3 
40, 40  -10.0 -4.2 -14.2   -2.3   -8.6 -10.9 
60, 60    -8.7 -9.1 -17.8   -3.4 -12.6 -16.0 
10, 30     0.4 -2.5   -2.1     0.1   -5.0   -4.9 
20, 60    -3.1 -6.3   -9.4   -3.2   -6.3   -9.5 
30, 90    -6.0 -3.7   -9.7   -6.6   -1.2   -7.8 
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Table 31 
Impact of PDI on X2 Distribution, Medium (0.5σ) Effect Size Rejection Rates 
  α = .01  α = .05 
  % Change in Rejection Rate  % Change in Rejection Rate 
n1, n2  10-30% 30-50% 10-50%  10-30% 30-50% 10-50% 
10, 10  -2.9   -2.1   -5.0   -2.8   -2.8   -5.6 
20, 20  -1.7   -2.9   -4.6   -2.6   -7.1   -9.7 
30, 30  -6.6   -5.6 -12.2   -6.1   -6.0 -12.1 
40, 40  -2.5 -10.4 -12.9   -6.2 -10.6 -16.8 
60, 60  -5.4 -12.1 -17.5   -4.4 -11.5 -15.9 
10, 30   2.6   -1.5    1.1   -0.2   -6.3   -6.5 
20, 60  -1.4   -2.6   -4.0   -2.9   -4.0   -6.9 
30, 90  -5.4   -3.5   -8.9   -7.0   -3.1 -10.1 
 
Table 32 
Impact of PDI on t Distribution, Medium (0.5σ) Effect Size Rejection Rates 
  α = .01  α = .05 
  % Change in Rejection Rate  % Change in Rejection Rate 
n1, n2  10-30% 30-50% 10-50%  10-30% 30-50% 10-50% 
10, 10  -1.3   -3.5   -4.8   -2.1        -7.9 -10.0 
20, 20  -4.6   -2.8   -7.4   -1.6        -6.3   -7.9 
30, 30  -5.0   -6.6 -11.6   -2.8        -9.4 -12.2 
40, 40  -2.1   -7.5   -9.6   -1.2      -10.1 -11.3 
60, 60  -6.7 -10.6 -17.3   -3.5        -8.5 -12.0 
10, 30  -2.0   -0.4   -2.4   -2.3        -2.0   -4.3 
20, 60   0.1   -5.3   -5.2    0.9        -3.1   -2.2 
30, 90  -0.7   -3.5   -4.2   -4.9        -2.4   -7.3 
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Table 33 
Impact of PDI on Normal Distribution, Large (0.8σ) Effect Size Rejection Rates 
  α = .01  α = .05 
  % Change in Rejection Rate  % Change in Rejection Rate 
n1, n2  10-30% 30-50% 10-50%  10-30% 30-50% 10-50% 
10, 10    -5.2   -6.3 -11.5   -6.4   -6.5 -12.9 
20, 20    -8.3 -11.6 -19.9   -9.6   -9.0 -18.6 
30, 30  -11.4 -12.4 -23.8   -3.9 -13.2 -17.1 
40, 40    -6.4 -15.5 -21.9   -5.7   -5.9 -11.6 
60, 60    -5.6 -10.6 -16.2   -2.5   -2.8   -5.3 
10, 30    -4.5   -2.2   -6.7   -2.0   -8.8 -10.8 
20, 60    -3.5   -8.6 -12.1   -2.1   -7.1   -9.2 
30, 90    -2.8   -8.5 -11.3   -1.0   -3.8   -4.8 
 
Table 34 
Impact of PDI on X2 Distribution, Large (0.8σ) Effect Size Rejection Rates 
  α = .01  α = .05 
  % Change in Rejection Rate  % Change in Rejection Rate 
n1, n2  10-30% 30-50% 10-50%  10-30% 30-50% 10-50% 
10, 10  -1.9   -9.4 -11.3   -3.6 -8.1     -11.7 
20, 20  -7.3 -10.5 -17.8   -4.8 -8.4     -13.2 
30, 30  -8.5 -15.5 -24.0   -3.9 -9.9     -13.8 
40, 40  -9.3   -8.3 -17.6   -2.0 -7.7       -9.7 
60, 60  -3.9 -10.2 -14.1   -2.0 -3.7       -5.7 
10, 30  -3.7   -3.6   -7.3   -3.1 -5.6       -8.7 
20, 60  -0.5   -6.9   -7.4   -3.0 -3.8       -6.8 
30, 90  -0.3   -8.4   -8.7   -2.2 -0.9       -3.1 
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Table 35 
Impact of PDI on t Distribution, Large (0.8σ) Effect Size Rejection Rates 
  α = .01  α = .05 
  % Change in Rejection Rate  % Change in Rejection Rate 
n1, n2  10-30% 30-50% 10-50%  10-30% 30-50% 10-50% 
10, 10  -5.5   -3.9   -9.4   -8.4 -8.7 -17.1 
20, 20  -4.1 -11.7 -15.8   -5.1 -9.9 -15.0 
30, 30  -7.4 -12.8 -20.2   -5.8 -6.1 -11.9 
40, 40  -5.6 -13.9 -19.5   -3.2 -7.4 -10.6 
60, 60  -3.4   -8.4 -11.8   -1.5 -2.8   -4.3 
10, 30  -2.5   -6.2   -8.7   -2.2 -3.5   -5.7 
20, 60  -3.4   -8.0 -11.4   -0.3 -5.4   -5.7 
30, 90  -5.9   -5.0 -10.9   -4.4  1.4   -3.0 
 
Table 36 
Impact of PDI on Normal Distribution, Very Large (1.2σ) Effect Size Rejection Rates 
  α = .01  α = .05 
  % Change in Rejection Rate  % Change in Rejection Rate 
n1, n2  10-30% 30-50% 10-50%  10-30% 30-50% 10-50% 
10, 10  -8.4 -11.2 -19.6   -4.5 -12.0 -16.5 
20, 20  -6.7 -18.8 -25.5   -2.9   -9.1 -12.0 
30, 30  -4.5   -8.2 -12.7   -1.2   -2.6   -3.8 
40, 40  -1.2   -5.0   -6.2   -0.1   -0.7   -0.8 
60, 60  -0.1   -0.6   -0.7    0.0    0.0    0.0 
10, 30  -3.1   -8.9 -12.0   -4.0   -6.8 -10.8 
20, 60  -1.1   -2.7   -3.8   -0.3   -2.3   -2.6 
30, 90  -0.2   -0.6   -0.8    0.0   -0.3   -0.3 
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Table 37 
Impact of PDI on X2 Distribution, Very Large (1.2σ) Effect Size Rejection Rates 
  α = .01  α = .05 
  % Change in Rejection Rate  % Change in Rejection Rate 
n1, n2  10-30% 30-50% 10-50%  10-30% 30-50% 10-50% 
10, 10  -8.4   -8.9 -17.3   -4.6 -8.5     -13.1 
20, 20  -6.3 -13.2 -19.5   -3.5 -5.3 -8.8 
30, 30  -5.1   -7.6 -12.7   -1.3 -2.1 -3.4 
40, 40  -2.7   -5.0   -7.7   -0.4 -0.6 -1.0 
60, 60  -0.5   -1.4   -1.9   -0.1  0.0 -0.1 
10, 30  -3.6   -6.0   -9.6   -4.2 -2.8 -7.0 
20, 60   1.1   -4.6   -3.5   -0.5 -1.3 -1.8 
30, 90   0.1   -1.0   -0.9   -0.1 -0.1 -0.2 
 
Table 38 
Impact of PDI on t Distribution, Very Large (1.2σ) Effect Size Rejection Rates 
  α = .01  α = .05 
  % Change in Rejection Rate  % Change in Rejection Rate 
n1, n2  10-30% 30-50% 10-50%  10-30% 30-50% 10-50% 
10, 10  -9.8 -9.5 -19.3   -5.8 -8.3 -14.1 
20, 20  -8.2 -8.3 -16.5   -3.0 -3.3   -6.3 
30, 30  -2.7 -7.0   -9.7   -0.6 -3.3   -3.9 
40, 40  -0.5 -6.7   -7.2   -0.8 -2.2   -3.0 
60, 60  -0.2 -1.9   -2.1    0.0 -0.3   -0.3 
10, 30  -4.2 -4.0   -8.2   -3.5 -2.5   -6.0 
20, 60  -1.1 -4.1   -5.2   -0.2 -1.4   -1.6 
30, 90  -0.7 -1.1   -1.8   -0.2 -0.2   -0.4 
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Table 39 
Impact of PDI on Normal Distribution, Huge (2.0σ) Effect Size Rejection Rates 
  α = .01  α = .05 
  % Change in Rejection Rate  % Change in Rejection Rate 
n1, n2  10-30% 30-50% 10-50%  10-30% 30-50% 10-50% 
10, 10  -6.3     -12.3 -18.6    -2.4 -6.3 -8.7 
20, 20  -0.3       -1.7   -2.0     0.0 -0.1 -0.1 
30, 30   0.0       -0.4   -0.4     0.0  0.0  0.0 
40, 40   0.0        0.0    0.0     0.0  0.0  0.0 
60, 60   0.0        0.0    0.0     0.0  0.0  0.0 
10, 30   0.1       -2.7   -2.6     0.0 -0.2 -0.2 
20, 60   0.0        0.0    0.0     0.0  0.0  0.0 
30, 90   0.0        0.0    0.0     0.0  0.0  0.0 
 
Table 40 
Impact of PDI on X2 Distribution, Huge (2.0σ) Effect Size Rejection Rates 
  α = .01  α = .05 
  % Change in Rejection Rate  % Change in Rejection Rate 
n1, n2  10-30% 30-50% 10-50%  10-30% 30-50% 10-50% 
10, 10  -3.4 -10.0 -13.4  -1.9 -5.9      -7.8 
20, 20  -1.0   -2.9   -3.9   0.3 -0.6      -0.3 
30, 30  -0.1   -1.6   -1.7  -0.1  0.1       0.0 
40, 40   0.0    0.0    0.0   0.0  0.0       0.0 
60, 60   0.0    0.0    0.0   0.0  0.0       0.0 
10, 30  -2.1   -3.2   -5.3   0.1 -1.1      -1.0 
20, 60   0.0   -0.2   -0.2   0.1 -0.1       0.0 
30, 90   0.0      0.0    0.0   0.0  0.0       0.0 
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Table 41 
Impact of PDI on t Distribution, Huge (2.0σ) Effect Size Rejection Rates 
  α = .01  α = .05 
  % Change in Rejection Rate  % Change in Rejection Rate 
n1, n2  10-30% 30-50% 10-50%  10-30% 30-50% 10-50% 
10, 10  -3.4 -7.5 -10.9  -2.0 -1.8 -3.8 
20, 20   0.4 -4.3   -3.9  -0.6 -1.2 -1.8 
30, 30  -0.2 -0.8   -1.0   0.0 -0.2 -0.2 
40, 40  -0.1 -0.1   -0.2   0.0  0.0  0.0 
60, 60   0.0  0.0    0.0   0.0  0.0  0.0 
10, 30  -0.8 -2.4   -3.2  -0.2 -1.2 -1.4 
20, 60  -0.2 -0.1   -0.3  -0.2 -0.1 -0.3 
30, 90   0.0 -0.1   -0.1   0.0  0.0  0.0 
 
 With a large (0.8σ) treatment effect (Tables 33 – 35), as the PDI increased from 10% to 
30%, the loss of power was 11.4% or less for the Normal and Chi-square distributions and 7.4% 
or less for the t distribution at alpha .01 regardless of sample size. At the .05 alpha level, the loss 
of power was 5.8% or less save for the 10, 10 and 20, 20 sample size levels regardless of 
distribution. As the PDI increased from 30% to 50%, the loss of power at alpha .01 was 15.5% or 
less regardless of sample size and distribution. At the .05 alpha level, the loss of power was 
13.2% or less for the Normal distribution and 9.9% or less for the Chi-square and t distributions 
regardless of sample size. As the PDI increased from 10% to 50%, the loss of power was 24% or 
less at alpha .01 and 18.6% or less at alpha .05 regardless of sample size and distribution.  
 With a very large (1.2σ) treatment effect (Tables 36 – 38), as the PDI increased from 
10% to 30%, the loss of power was 5.1% or less save for the 10, 10 and 20, 20 sample size levels 
at alpha .01 regardless of distribution. At the .05 alpha level, the loss of power was 1.3% or less 
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save for the 10, 10 and 20, 20 balanced sample size levels and the 10, 30 unbalanced sample size 
level regardless of distribution. As the PDI increased from 30% to 50%, the loss of power was 
8.9% or less save for the 10, 10 and 20, 20 sample size levels at alpha .01 regardless of 
distribution. At alpha .05, the loss of power was 3.3% or less save for the 10, 10 and 20, 20 
balanced sample size levels and the 10, 30 unbalanced sample size level regardless of 
distribution. As the PDI increased from 10% to 50%, the loss of power was 12.7% or less at 
alpha .01 regardless of sample size and distribution. At the .05 alpha level, the loss of power was 
3.9% or less save for the 10, 10 and 20, 20 balanced sample size levels and the 10, 30 
unbalanced sample size level regardless of distribution.  
 With a huge (2.0σ) treatment effect (Tables 39 – 41), the PDI had virtually no impact on 
rejection rates save for the 10, 10 and 20, 20 balanced sample size levels and the 10, 30 
unbalanced sample size level regardless of distribution and alpha.  
 In conclusion, one of the strengths of multiple imputation is that it has power advantages 
over traditional missing data methods (see Chapter 2). As the results from this simulation 
indicate that there can be a loss of power when MI is utilized using the defaults in SPSS (m = 5, 
iterations = 10) and a limited imputation model (one auxiliary variable with r = .50), it is 
recommended that clinicians plan for the treatment of missing data in the design stage to reduce 
the probability of making a Type II error. 
Limitations of the Study 
 Some degree of caution is warranted when generalizing the results of simulation studies 
to a broad range of settings. This study was conducted using SPSS; the use of other software 
could potentially affect results (e.g., Allison, 2000; Von Hippel, 2004). Imputations were 
generated using 10 iterations and m = 5. Changing either (or both) of these simulation 
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characteristics could affect rejection rates. One auxiliary variable (r = .50) was included in the 
imputation model, adding additional variables or changing the correlation of the variable in the 
model (see chapter 2) could affect results. Any generalizations should be limited to the factor 
levels simulated in this study. 
Scope for Future Research 
 There are two key ways that this research could be extended. First, this Monte Carlo 
simulation investigated three theoretical distributions. As public access to clinical trial data 
increases, clinicians could improve the ecological validity of this research by estimating real 
clinical distributions. Second, this research was conducted under the MCAR assumption. It could 
be extended by examining missing data created under the MNAR mechanism. Of special interest 
would be an investigation into MI’s limitations when the missing data follow an exceptionally 
complex pattern. 
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The National Academy of Science identified numerous high priority areas for missing 
data research. This study addresses several of those areas by systematically investigating the 
impact of multiple imputation on the rejection rate of the independent samples t test under 
varying conditions of sample size, effect size, fraction of missing data, distribution shape, and 
alpha. In addition to addressing gaps in the missing data literature, this study also provides an 
overview of the multiple imputation procedure, as implemented in SPSS, with a focus on the 
practical aspects and challenges of using this method.  
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